As Biotechnology businesses, Arcus Biosciences Inc. (NYSE:RCUS) and Kazia Therapeutics Limited (NASDAQ:KZIA), are affected by contrast. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences Inc.	8.35M	60.94	49.59M	-1.18	0.00
Kazia Therapeutics Limited	N/A	0.00	N/A	-0.89	0.00

Table 1 highlights Arcus Biosciences Inc. and Kazia Therapeutics Limited’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Arcus Biosciences Inc. and Kazia Therapeutics Limited.

	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences Inc.	-593.89%	0%	0%
Kazia Therapeutics Limited	0.00%	0%	0%

Liquidity

The Current Ratio and a Quick Ratio of Arcus Biosciences Inc. are 16 and 16. Competitively, Kazia Therapeutics Limited has 3.6 and 3.6 for Current and Quick Ratio. Arcus Biosciences Inc.’s better ability to pay short and long-term obligations than Kazia Therapeutics Limited.

Institutional and Insider Ownership

The shares of both Arcus Biosciences Inc. and Kazia Therapeutics Limited are owned by institutional investors at 50.2% and 2.5% respectively. Insiders owned 0.9% of Arcus Biosciences Inc. shares. Competitively, Kazia Therapeutics Limited has 28.8% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Arcus Biosciences Inc.	2.04%	17.99%	4.17%	-13.85%	0%	11.42%
Kazia Therapeutics Limited	11.59%	13.84%	47.51%	9.07%	-11.9%	58.44%

For the past year Arcus Biosciences Inc. was less bullish than Kazia Therapeutics Limited.

Summary

Kazia Therapeutics Limited beats Arcus Biosciences Inc. on 4 of the 7 factors.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.

Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. The company is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. It has collaboration agreement with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.